| 标题： | 炎性乳腺癌诊治临床实践指南2022.V1（CSBrS-Guideline-21) |
| title： | Clinical practice guidelines for the diagnosis and treatment of inflammatory breast cancer 2022.V1（CSBrS-Guideline-21) |
| 版本： | 原创版 |
| version： | Original |
| 分类： | 专家共识 |
| classification： | Experts consensus |
| 领域： | 诊疗 |
| field： | Diagnosis and Treatment |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 中国乳腺疾病领域专家及相关医疗工作者 |
| Guide users： | Chinese breast diseases specialists and related medical workers |
| 证据分级方法： | 无 |
| Evidence grading method： | None |
| 制定单位： | 中华医学会外科学分会乳腺外科学组 |
| Formulating unit： | the Chinese Society of Breast Surgery (CSBrS) of the Chinese Medical Association |
| 注册时间： | 2022-01-23 |
| Registration time： | |
| 注册编号： | IPGRP-2022CN046 |
| Registration number： | |
| 指南制订的目的： | 为提高炎性乳腺癌（inflammatory breast cancer，IBC）临床诊治水平，中华医学会外科学分会组织专家通过文献调研和讨论，提出与IBC临床实践相关的关键临床问题，参照GRADE（Grading of Recommendations Assessment, Development and Evaluation）系统对相关证据进行评价，并结合中国临床可及性，制定中华医学会IBC临床实践指南，旨在为中国乳腺癌及其他专业医师提供参考借鉴。 |
| Purpose of the guideline： | In order to improve the clinical diagnosis and treatment of inflammatory breast cancer (IBC), the Chinese Medical Association Surgery Branch organized experts to put forward key clinical issues related to the clinical practice of IBC through literature research and discussion. Development and Evaluation) system to evaluate relevant evidence, and combined with clinical accessibility in China, the Chinese Medical Association IBC clinical practice guidelines are formulated, aiming to provide reference for Chinese breast cancer and other professional physicians. |
